Blood biomarkers to predict cognitive/functional decline and mortality in hospitalized older adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

BAD-GER is a multicenter, prospective, three-arm observational project that will collect blood from hospitalized older adults to validate a prognostic algorithm derived from a retrospective discovery cohort of 700 geriatric patients. The study measures plasma levels of Alzheimer's and neuro-injury biomarkers (Aβ42, total and phosphorylated tau, NfL, GFAP), chemokines (CXCL8, CXCL12), and metabolites via metabolomics alongside routine labs and clinical data. Investigators will integrate these biomarkers with immunophenotypes and clinical measures to see if they predict functional/cognitive decline, short-term and one-year mortality, and hospital readmission. Participants are enrolled in three groups—acute neurological inpatients, non-neurological inpatients with dementia, and non-neurological inpatients without dementia—and will have blood collected for analysis and follow-up.

Why it matters

Who can join: the full rules

GROUP 1: Patients hospitalized for acute neurological disorders

Inclusion criteria:

* Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis

Exclusion criteria:

* no informed consent

GROUP 2: Patients hospitalized for non-neurological diseases with dementia

Inclusion criteria:

* inpatients with diagnosis of major neurocognitive disorder according to DSM-5 criteria (2013)

Exclusion criteria:

* Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis
* no informed consent

GROUP 3: Patients hospitalized for non-neurological diseases without dementia

Inclusion criteria:

* inpatients with non-neurological diseases

Exclusion criteria:

* inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis
* diagnosis of dementia
* no informed consent

Where it's running

• IRCCS INRCA Hospital
  Ancona, Italy Recruiting
• IRCCS INRCA Hospital
  Fermo, Italy Recruiting
• Policlinico Universitario
  Messina, Italy Recruiting

Study contacts

• Study coordinator: Anna Rita Bonfigli
• Email: a.bonfigli@inrca.it
• Phone: +390718003719

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Norms for a Voice-Based Digital Cognitive Test Across Ages

  This study tests a voice-enabled digital cognitive test to establish normal scores for adults aged 18–100.

  Recruiting The Neurology Center of Southern California · Carlsbad, California · NCT07763392

• Lived Experience Narratives in Dementia

  This project tests a digital Online LEND Intervention that shares dementia patients’ and caregivers’ lived experiences to see if it helps wellbeing and connection.

  Recruiting at 2 sites University of Nottingham · Nottingham, England and 1 other locations · NCT07757178

• Blood tests using plasma biomarkers to diagnose and track Alzheimer’s disease

  A large, year-long study in Milan is testing whether blood markers can help diagnose Alzheimer’s and predict how it will progress in people with memory concerns.

  Recruiting IRCCS San Raffaele · Milan, Milano · NCT07717567

• Far-Infrared Therapy for Alzheimer’s Disease Dementia

  This trial tests whether a far-infrared radiator can help people with Alzheimer's-related dementia who are on stable dementia medications.

  Recruiting National Defense Medical Center, Taiwan · Taipei · NCT07672171

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.